NanoImaging Services Expands Horizons with Proteos Deal
NanoImaging Services (NIS), a prominent provider of cryo-electron microscopy (cryo-EM) services, has announced an exciting acquisition of Proteos, Inc., a respected contract research organization (CRO) known for its high-quality protein production services. This strategic partnership is designed to elevate the integrated protein sciences and structure-based discovery capabilities of both organizations, allowing for even more innovative approaches to drug discovery and development.
A New Chapter in Protein Sciences
This acquisition signifies a pivotal moment for NIS as it officially joins forces with Proteos, which has been dedicated to delivering exceptional recombinant protein and antibody production, purification, and analytical services. The collaboration seeks to create a comprehensive platform for customers engaging in structure-based drug discovery, combining the robust capabilities of NIS's cryo-EM technology with Proteos' specialization in protein production.
Leadership Vision
John Rigg, the CEO of NIS, expressed enthusiasm about welcoming the Proteos team into the NIS family. He emphasized that this union will enhance their commitment to cutting-edge science and superior service. The leaders from both organizations aim to harness their combined strengths to address the dynamic landscape of structural biology and protein production.
Customer-Centric Approach
Mary Shuck, CEO of Proteos, highlighted the synergies shared between the two companies, pointing out that both are focused on enhancing customer experiences through scientific excellence. With access to more resources, Proteos aims to better serve its clients and lead innovations in structural biology.
Strengthening Market Position
NIS’s acquisition of Proteos is backed by Ampersand Capital Partners, a global investment firm known for its commitment to growth within the healthcare sector. David Parker, a general partner at Ampersand, noted that merging NIS and Proteos is a crucial advancement to meet the fast-changing demands of drug discovery. This partnership positions NIS as a one-stop-shop for customers looking to develop therapeutic candidates or produce target proteins efficiently.
Business Impacts
The union between these two leaders in protein sciences is expected to drive forward innovation in structural biology. The combination of NIS’s state-of-the-art cryo-EM capabilities with Proteos’ extensive protein production experience creates a powerful resource for researchers in the pharmaceutical and biotechnology sectors.
About NanoImaging Services
NanoImaging Services has developed a reputation for expertise, reliability, and collaborative efforts since its founding in 2007. The company has established itself as a premier provider of imaging services to the pharmaceutical and biotechnology communities, with cutting-edge facilities stocked with advanced electron microscopy equipment designed to support intricate structural biology workflows. This acquisition enhances its already comprehensive portfolio of services tailored for the life sciences market.
About Proteos, Inc.
Proteos, a trusted partner to the biotech industry, specializes in producing high-quality data and recombinant proteins to aid discovery research. Founded with a mission to support exploratory research, Proteos has a team of experienced professionals committed to delivering exceptional quality in its services. This acquisition enables Proteos to expand its offerings and impact, paving the way for enhanced capabilities in the life sciences.
About Ampersand Capital Partners
Ampersand Capital Partners has been a significant player in private equity since its founding in 1988, focusing on growth investments in healthcare. With an impressive portfolio, Ampersand fosters long-term value across its partnerships, supporting companies like NIS to achieve their ambitious goals and respond to evolving market needs.
Frequently Asked Questions
What does the acquisition of Proteos mean for NIS?
The acquisition enhances NIS's capabilities in structural biology and integrates their services for more comprehensive solutions in drug discovery.
Who are the key leaders involved in this acquisition?
John Rigg, CEO of NIS, and Mary Shuck, CEO of Proteos, are the prominent figures leading this partnership, along with support from Ampersand Capital Partners.
What expertise does Proteos bring to NIS?
Proteos offers significant experience in high-quality protein production, which complements NIS’s cryo-EM services to create an integrated protein sciences solution.
How will this partnership impact customers?
Customers can expect improved services and innovation in structural biology, providing a more effective means of developing therapeutic candidates.
What is NanoImaging Services known for?
NanoImaging Services is celebrated for its leadership in cryo-EM services and its commitment to advancing scientific understanding in the drug discovery process.
